Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions

doi:10.3748/wjg.v23.i32.5875

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11868)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

1132

WORD

218

HTML

7896

Figures (1-1)

205

Tables (1-3)

174

Sum=9625

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1066

Download

1177

Sum=2243

Aug 28, 2017 (publication date) through May 12, 2024

Times Cited of This Article

Times Cited (69)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875

Table 3 Principal clinical trials with nab-paclitaxel in pancreatic cancer “early settings”

Study ID	Setting	Study drugs	Phase	Status
NCT01964430	Adjuvant	Nab-paclitaxel + Gemcitabine vs Gemcitabine	III	Recruiting
NCT02506842	Adjuvant	Nab-paclitaxel + Gemcitabine vs OFF	III	Recruiting
NCT02023021	Adjuvant	Nab-paclitaxel + Gemcitabine	II	Recruiting
NCT02125136	Neoadjuvant	Nab-paclitaxel + Gemcitabine vs FOLFIFINOX	II	Recruiting
NCT02243007	Neoadjuvant	Nab-paclitaxel + Gemcitabine vs FOLFIFINOX	II	Recruiting
NCT02717091	Neoadjuvant/borderline resectable	Nab-paclitaxel + Gemcitabine vs FOLFIFINOX	II	Recruiting
NCT02481635	NEO/adjuvant	Nab-paclitaxel + Gemcitabine + radiotherapy	I-II	Recruiting
NCT01431794	Neoadjuvant	Nab-paclitaxel + Gemcitabine + LDE-225	I-II	Active not recruiting
NCT02588443	NEO/adjuvant	Nab-paclitaxel + Gemcitabine + RO7009789	I	Recruiting
NCT02272738	Neoadjuvant	Nab-paclitaxel + Gemcitabine + radiotherapy	I	Recruiting
NCT02506803	Neoadjuvant	Nab-paclitaxel + Gemcitabine	I	Recruiting
NCT02427841	Resectable	Nab-paclitaxel + Gemcitabine followed by radiotherapy	II	Recruiting
NCT02550327	Resectable	Nab-paclitaxel + Gemcitabine + Cisplatin + Anakinra	I	Recruiting
NCT02210559	Locally advanced	Nab-paclitaxel + Gemcitabine + FG-3019	I-II	Recruiting
NCT02394535	Locally advanced	Nab-paclitaxel + Capecitabine + radiotherapy	I	Recruiting
NCT02124369	Borderline unresectable	Nab-paclitaxel + Gemcitabine	II	Recruiting
NCT02043730	Unresectable locally advaced	Nab-paclitaxel + Gemcitabine	II	Recruiting
NCT02207465	Unresectable locally advanced	Nab-paclitaxel + Gemcitabine + radiotherapy	I	Recruiting
NCT02272738	Unresectable locally advanced	Nab-paclitaxel + Gemcitabine	I	Recruiting
NCT01978184	Preoperative	Nab-paclitaxel + Gemcitabine + Hydroxychloroquine	II	Recruiting
NCT02427841	Preoperative	Nab-paclitaxel + Gemcitabine + radiotherapy	II	Recruiting
NCT02723331	Preoperative	Nab-paclitaxel + Gemcitabine followed by SBRT	II	Recruiting
NCT02930902	Preoperative	Nab-paclitaxel + Gemcitabine + Pembrolizumab + Paricalcitol	I	Recruiting

SBRT: Stereotactic body radiotherapy; OFF: Oxaliplatin plus fluoro-folate.

Citation: Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886
URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5875.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5875